Firefly Neuroscience is trading 7.03% down at $1.19 amid profit-taking and volatility following its sharp prior-session advance.
- It closed at $1.28 on September 17, 2026, after a 37.62% rally.
- Firefly announced a strategic collaboration with Radial involving its FDA-cleared Evoke platform, but no confirmed new catalyst directly explains the decline.
- The broader market is mixed, offering limited support for a market-wide explanation.